<DOC>
	<DOCNO>NCT01276704</DOCNO>
	<brief_summary>The investigator would like see woman increase risk breast cancer likely tolerate SDG daily 12 month without significant side effect change menstrual cycle . The investigator would also like determine Brevail® reduce breast cell proliferation pre-menopausal woman .</brief_summary>
	<brief_title>Prevention Strategy Pre-Menopausal Women High Risk Development Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Secoisolariciresinol</mesh_term>
	<criteria>PARTICIPANT SELECTION Risk Level Required RPFNA Screening Eligibility Given low probability side effect desire able generalize result moderate well high risk population , target cohort premenopausal woman relative risk breast cancer 2fold great average woman age group virtue one follow condition : A 1st 2nd degree relative breast cancer diagnose age 60 A prior biopsy indicate proliferative breast disease , atypical hyperplasia , LCIS Multiple prior breast biopsy regardless histology 50 % high estimate mammographic density visual inspection Prior current RPFNA evidence atypia Known carrier BRCA1 2 mutation . Age , LifeStyle Medical Eligibility Criteria Tissue Screening Candidates tissue screen study premenopausal woman meet risk criterion follow demographic medical criterion : Age 21 49 ( limit maximum age 49 reduce possibility reduction Ki67 due entry menopause transition study ) . Stable hormonal status previous 6 month ( stop start oral contraceptive , experienced lactation pregnancy ) willing maintain status study . BMI &lt; 40 kg/m2 . Has least 4 menstrual cycle past year If regularly undergo screen mammography , must perform within 9 month prior baseline RPFNA , interpret suspicious breast cancer Breast exam interpret normal ( suspicious cancer ) . Exclusion Criteria Screening RPFNA Study Participation Candidates ineligible tissue screen meet following condition : Consumption systemic antibiotic 3 week prior baseline RPFNA . Systemic antibiotic reduce intestinal bacteria thus ability convert SECO ENL [ 104 ] . Consumption supplement contain SDG ( flaxseed sesame seed ) 3 week prior baseline RPFNA . ( Consumption food contain flaxseed sesame seed OK. ) Use selective estrogen receptor modulator aromatase inhibitor ( tamoxifen , raloxifene , arzoxifene , acolbifine , anastrozole , exemestane , letrozole ) within previous 6 month . Currently enrol interventional investigational study . Bilateral breast implant . Invasive breast cancer invasive cancer diagnosis within five year . Metastatic malignancy kind.excluding Hodgkin 's nonHodgkin 's lymphoma . Current anticoagulant use . Consumption coumadin , fish oil , anticoagulants 3 week prior baseline RPFNA . Any condition intercurrent illness opinion investigator make subject poor candidate RPFNA trial . Inclusion Criteria Study Entry RPFNA perform follicular portion ( day 110 ) menstrual cycle . Note day 1 define first day bleeding . RPFNA specimen exhibit hyperplasia +/ atypia ( Masood score ≥13 ) ≥500 cell cytology slide . Ki67 ≥2 % positivity ( ≥500 cell ) . Willing continue without oral contraceptive throughout duration study participation ( 12 month ) . Nonoral contraceptive permissible . If heterosexually active , must agreeable use nonhormonal form contraception trial husband partner must vasectomy . ( Safety SDG pregnancy document ) . Have reasonable organ function document metabolic chemistry profile . Willing undergo history physical baseline 12 month contact periodically trial coordinator 12 month study period . Willing blood drawn baseline twelve month . Able understand willing provide inform consent RPFNA 's study participation .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>